Related Experiment Videos
[Lipoprotein (a) and diabetes: relationship based on 224 cases]
J M Taupin1, V Durlach, M Hassaim
1Clinique Médicale, Hôpital Robert Debré, Reims, France.
Diabete & Metabolisme
|March 1, 1993
Summary
Plasma lipoprotein(a) levels did not differ between diabetic and non-diabetic individuals. Achieving normal blood sugar levels did not impact lipoprotein(a) concentrations in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Elevated lipoprotein(a) [Lp(a)] is a suspected contributor to coronary heart disease (CHD) in diabetes, but existing data are conflicting.
- Understanding the relationship between Lp(a) and diabetes is crucial for managing cardiovascular risk.
Purpose of the Study:
- To investigate the distribution of plasma Lp(a) in diabetic subjects compared to non-diabetic controls.
- To assess the impact of glycaemic control and short-term normoglycaemia on Lp(a) levels in insulin-requiring diabetic patients.
Main Methods:
- Plasma Lp(a) levels were measured using radial immunodiffusion in 224 diabetic patients and 92 controls.
- Triglycerides (TG) and glucose levels were evaluated in 16 insulin-requiring diabetics before and after 10 days of normoglycaemia.
- Glycaemic control was assessed using HbA1c.
Main Results:
- Plasma Lp(a) distribution was similar between diabetic and non-diabetic individuals, as well as between Type 1 and Type 2 diabetics.
- No significant correlation was found between Lp(a) levels and HbA1c (glycaemic control).
- Short-term normalization of glycaemia did not alter plasma Lp(a) levels, with no significant correlation observed between variations in glycaemia or triglyceridaemia and Lp(a).
Conclusions:
- Plasma Lp(a) distribution is comparable in diabetic and non-diabetic populations.
- Lp(a) concentrations appear unaffected by chronic hyperglycaemia or rapid glycaemic normalization in diabetics.
- Standardization of Lp(a) assays is essential for definitive conclusions; management should focus on other vascular risk factors due to the lack of effective Lp(a)-lowering treatments.